Liquent, Inc. Acquired by Marlin Equity Partners

HORSHAM, Pennsylvania, January 6 - Liquent, Inc. ("Liquent"), a leading provider of software and service
solutions designed to support the regulatory business processes of life
sciences companies, is pleased to announce that it has been acquired by
Marlin Equity Partners ("Marlin") from Thomson Reuters. Based in Los Angeles,
CA, Marlin is a leading private investment firm with over US$1 billion of
capital under management.

Liquent is the provider of Liquent InSight(R), the industry's only fully
integrated and scalable regulatory information management platform. InSight
can be leveraged throughout a client organization in support of a life
sciences company's development, registration, and manufacturing processes.
Through its Regulatory and Clinical Services consulting services team,
Liquent also provides a full range of outsourcing services to support the
regulatory submission and registration management activities of a life
sciences company. Liquent's current General Manager, Rick Riegel, will
continue his leadership position as the CEO of the company.

"We are very excited to be partnering with such a strong private equity
firm," commented Rick Riegel. "Marlin brings substantial financial resources
and expertise in the healthcare IT sector. With their backing and Liquent's
comprehensive software and service solutions, industry leadership, and focus
on customer service, we look forward to accelerating our growth and ability
to service the evolving and rapidly changing needs of the life sciences
industry."

"Marlin recognizes the life sciences industry's constant struggle with
regulatory change, new product approvals, and cost pressures. Marlin's
backing combined with Liquent's software and outsourcing capabilities
positions us well in helping our customers solve complex regulatory
challenges," stated Jim Brady, Healthcare Operating Partner at Marlin Equity
Partners.

About Marlin Equity Partners

Marlin Equity Partners is a Los Angeles, California-based private
investment firm with over US$1 billion of capital under management. The firm
is focused on providing corporate parents, shareholders and other
stakeholders with tailored solutions that meet their business and liquidity
needs in special situations. Marlin invests in businesses across multiple
industries that are in the process of undergoing varying degrees of
operational, financial or market-driven change where its capital base,
industry relationships and extensive network of operational resources
significantly strengthens a company's outlook and enhances value. Since its
inception, Marlin, through its group of funds and related companies, has
successfully completed over 30 acquisitions. For more information, please
visit www.marlinequity.com.

About Liquent, Inc.

Liquent regulatory solutions provide software and related regulatory and
clinical services for the life sciences industry. These solutions and
services help ensure clients meet the strict standards of regulatory
authorities across the world helping them achieve quality, accuracy, and data
integrity to deliver regulatory reports and submissions reliably and on time.

As a result, global life sciences companies, small tier to large tier,
rely on Liquent regulatory solutions to provide the technology and services
to compress the regulatory submissions and approval process, improving speed
to market, cost control, and productivity, all of which contribute to
ensuring patients' and physicians' timely access to new drugs. Over the last
decade, thousands of regulatory submissions have been produced using Liquent
world-class products and expert services. For more information please visit,
www.liquent.com.

    Contact: Rick Riegel
             Chief Executive Officer
             +1-215-328-4302

Rick Riegel, Chief Executive Officer, Liquent, Inc., +1-215-328-4302